ISTH Academy

Create Account Sign In
Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

Click here to join ISTH or renew your membership.

You may also access ISTH content "anytime, anywhere" with the FREE ISTH Academy App for iOS and Android.

Abstract
Discussion Forum (0)
Rate & Comment (0)
Main Topic: Diagnostics and OMICs

Category: Laboratory Diagnostics

PB0669
Effects of Anticoagulants and Common Interfering Substances on Four Commercially Available dRVVT Assays
A. Sadeghi-Khomami1, D. Lamont2, M. Boylan2, R. Clarke2, N. Kesavan2, C. Douglas2, K. Black2
1Precision BioLogic, Dartmouth, Canada, 2Precisionbiologic, Dartmouth, Canada

Background: dRVVT (dilute Russell's Viper Venom Time) is a popular assay for detection of lupus anticoagulants (LA), a marker of thrombophilia. Anticoagulant-free plasma samples are ideal for LA testing but not always feasible because anticoagulant therapy is a common thrombosis treatment. Anticoagulant interference may impact dRVVT results, affecting diagnosis.
Aims: We evaluated effects of numerous anticoagulants and common interferents on four commercial dRVVT assays to compare assay-specific impacts to LA diagnosis.
Methods: Precision BioLogic Inc. (PBI) dRVVT screening and confirmatory assays were performed on three analyzers - Stago Evolution (mechanical), IL ACL-TOP (optical) and Siemens BCS XP (optical) - and compared with the respective manufacturer's dRVVT assay. Plasma samples spiked with matrix blank or interferent were tested in quintuplicate according to the manufacturer's test application. Interferents were: Heparins (UFH, LMWH, Enoxaparin; 1 U/mL), Argatroban 1.5 µg/mL, Fondaparinux 1.25 µg/mL, Rivaroxaban 0.4 µg/mL and VKA plasma from patients on warfarin (INR< 3, N=10). HIL spiked samples (Hemoglobin 250 mg/dL, Bilirubin 2.5 mg/dL, Intralipid ~500 mg/dL) were also tested.
Results: Heparins and HIL did not affect results. However, both optical analyzers failed to detect clots in intralipid-spiked samples. FIIa inhibitor argatroban had no diagnostic impact, except it produced errors with IL ACL TOP, precluding results. FXa inhibitor fondaparinux did not affect results, but rivaroxaban caused false positive results with Siemens, Stago and IL reagents while PBI diagnostic results were unaffected. VKA (warfarin) had a similar impact; using Siemens, Stago and IL reagents, false positive results were observed in some samples while PBI results were correctly identified as LA negative.
Conclusions: Due to differences in test systems, different influences by DOACs and warfarin on dRVVT results can be expected. Notably, samples containing rivaroxaban or VKA would be correctly diagnosed with PBI reagents but might be incorrectly diagnosed false positive with Siemens, Stago or IL dRVVT reagents.
Main Topic: Diagnostics and OMICs

Category: Laboratory Diagnostics

PB0669
Effects of Anticoagulants and Common Interfering Substances on Four Commercially Available dRVVT Assays
A. Sadeghi-Khomami1, D. Lamont2, M. Boylan2, R. Clarke2, N. Kesavan2, C. Douglas2, K. Black2
1Precision BioLogic, Dartmouth, Canada, 2Precisionbiologic, Dartmouth, Canada

Background: dRVVT (dilute Russell's Viper Venom Time) is a popular assay for detection of lupus anticoagulants (LA), a marker of thrombophilia. Anticoagulant-free plasma samples are ideal for LA testing but not always feasible because anticoagulant therapy is a common thrombosis treatment. Anticoagulant interference may impact dRVVT results, affecting diagnosis.
Aims: We evaluated effects of numerous anticoagulants and common interferents on four commercial dRVVT assays to compare assay-specific impacts to LA diagnosis.
Methods: Precision BioLogic Inc. (PBI) dRVVT screening and confirmatory assays were performed on three analyzers - Stago Evolution (mechanical), IL ACL-TOP (optical) and Siemens BCS XP (optical) - and compared with the respective manufacturer's dRVVT assay. Plasma samples spiked with matrix blank or interferent were tested in quintuplicate according to the manufacturer's test application. Interferents were: Heparins (UFH, LMWH, Enoxaparin; 1 U/mL), Argatroban 1.5 µg/mL, Fondaparinux 1.25 µg/mL, Rivaroxaban 0.4 µg/mL and VKA plasma from patients on warfarin (INR< 3, N=10). HIL spiked samples (Hemoglobin 250 mg/dL, Bilirubin 2.5 mg/dL, Intralipid ~500 mg/dL) were also tested.
Results: Heparins and HIL did not affect results. However, both optical analyzers failed to detect clots in intralipid-spiked samples. FIIa inhibitor argatroban had no diagnostic impact, except it produced errors with IL ACL TOP, precluding results. FXa inhibitor fondaparinux did not affect results, but rivaroxaban caused false positive results with Siemens, Stago and IL reagents while PBI diagnostic results were unaffected. VKA (warfarin) had a similar impact; using Siemens, Stago and IL reagents, false positive results were observed in some samples while PBI results were correctly identified as LA negative.
Conclusions: Due to differences in test systems, different influences by DOACs and warfarin on dRVVT results can be expected. Notably, samples containing rivaroxaban or VKA would be correctly diagnosed with PBI reagents but might be incorrectly diagnosed false positive with Siemens, Stago or IL dRVVT reagents.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies